Dr. Amitabha Mazumder, MD

Dr. Mazumder practices at Cdms Surgery Center Inc in Pasadena, California.

Dr. Mazumder's NPI, 1881682318, was assigned on October 10, 2005. Dr. Mazumder graduated from The Johns Hopkins University School of Medicine in 1977. Dr. Mazumder holds California license G56488.

Dr. Mazumder's primary practice is Cdms Surgery Center Inc, at 50 Bellefontaine St, Pasadena, CA 91105 in Los Angeles County. The practice phone is (626) 654-3376.

Dr. Mazumder's primary practice is Cdms Surgery Center Inc in Pasadena, California. The medical group on file is The Oncology Institute of Hope and Innovation. Dmand AI also links Dr. Mazumder to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mazumder practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mazumder's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mazumder is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Mazumder's licenses on file in 5 states: California, New York, District of Columbia, Maryland and Texas.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Mazumder treats.

CMS data shows 364 Medicare services from Dr. Mazumder across 5 procedure codes in 2024, for 114 Medicare patients. Medicare paid $31,949 for them. Every service was in an office.

CMS counts 114 Medicare patients who saw Dr. Mazumder in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 77% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mazumder's median patient age at 63, with 66% women.

In 2024, Dr. Mazumder wrote 1,500 Medicare Part D claims for 250 patients. 66% of them were for generic drugs. CMS names the drug for 1,193 of them, across 33 drugs with 11 or more claims each, at $3,268,599 in total drug cost. In 2023, CMS named 1,008 claims across 29 drugs.

Dr. Mazumder accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 110 papers to Dr. Mazumder, published from 2006 to 2025. 2012 was the busiest year, with 5. The most frequent topics are Multiple Myeloma, Interleukin-2 and Cytotoxicity, Immunologic. Dr. Mazumder has published most often in Bone Marrow Transplant. Dr. Mazumder's most frequent co-authors are Sundar Jagannath, MD, Udit Narain Verma, MD and Sagar Lonial, MD.

Dmand AI links Dr. Mazumder to 10 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Multiple Myeloma and Primary Myelofibrosis. Karyopharm Therapeutics Inc sponsors the most, 6.

CMS Open Payments shows 1,843 general payments to Dr. Mazumder from 83 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Millennium Pharmaceuticals, Inc. paid the most, $363,472.

Dr. Mazumder graduated from The Johns Hopkins University School of Medicine in 1977.

Dr. Mazumder is in network with 17 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.